View ValuationSysmex 향후 성장Future 기준 점검 3/6Sysmex (는) 각각 연간 12% 및 6.6% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 12.1% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 12.1% 로 예상됩니다.핵심 정보12.0%이익 성장률12.06%EPS 성장률Medical Equipment 이익 성장0%매출 성장률6.6%향후 자기자본이익률12.07%애널리스트 커버리지Good마지막 업데이트14 Nov 2025최근 향후 성장 업데이트공고 • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.공고 • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.모든 업데이트 보기Recent updates공고 • Jun 06Sysmex Corporation to Report Q1, 2027 Results on Aug 07, 2026Sysmex Corporation announced that they will report Q1, 2027 results on Aug 07, 2026공고 • May 15Sysmex Corporation, Annual General Meeting, Jun 26, 2026Sysmex Corporation, Annual General Meeting, Jun 26, 2026.공고 • Apr 02Sysmex Corporation to Report Fiscal Year 2026 Results on May 14, 2026Sysmex Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 14, 2026공고 • Mar 26Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. Denka Company Limited intends to launch a Squeeze-Out Procedures, if it acquires the minimum tender shares (1,990,000 shares) and fails to acquire all of the KAINOS Laboratories, Inc's Shares (excluding the Shares Agreed Not to Be Tendered and treasury shares). The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders on March 25, 2026. Upon closing of the offer period, 3,223,919 shares were tendered. Since it is more than the minimum number of shares to be purchased (1,990,000 shares), Denka Company Limited will purchase all of the Tendered Share Certificates and intends to implement a series of procedures for the purpose of making the Tender Offeror the sole shareholder of KAINOS Laboratories, Inc. As of today, the KAINOS Laboratories, Inc's Shares are listed on the Standard Market of the Tokyo Stock Exchange. If the procedures are implemented, the KAINOS Laboratories, Inc's Shares will be delisted pursuant to the prescribed procedures, in accordance with the criteria for delisting of Tokyo Stock Exchange. KAINOS Laboratories, Inc's Shares, after being delisted, will no longer be traded on the Standard Market of the Tokyo Stock Exchange.공고 • Mar 05Sysmex Corporation (TSE:6869) announces an Equity Buyback for 30,000,000 shares, representing 4.81% for ¥30,000 million.Sysmex Corporation (TSE:6869) announces a share repurchase program. Under the program, the company will repurchase up to 30,000,000 shares, representing 4.81% of its issued share capital, for ¥30,000 million. The program will be valid till September 18, 2026. The purpose of the program is to improve capital efficiency and enhance shareholder returns as well as active business investment for our future growth. The purchased shares will be cancelled. As of December 31, 2025, the company had 623,180,031 outstanding shares (excluding treasury stock) and 6,300,045 treasury shares.공고 • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.공고 • Feb 12Sysmex Corporation Announces Executive and Board Changes, Effective April 1, 2026Sysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 12, 2026, to change the representative directors as stated below. Reasons for Change. To further strengthen management structure in order to enhance corporate value. Iwane Matsui has been newly appointed as the President (Representative Director), while previously serving as Member of the Managing Board and Senior Executive Officer, Senior Managing Director. Kaoru Asano appointed as the Member of the Managing Board, from currently holding the title of President (Representative Director). Effective Date of Transfer: April 1, 2026. Kaoru Asano is scheduled to resign from the Member of the Managing Board at the Ordinary General Meeting of Shareholders to be held in June 2026 and subsequently serve as Senior Executive Advisor. There are no changes to Hisashi Ietsugu's current position as Chairperson and Group CEO. Iwane Matsui was born on January 1, 1961, and graduated from Kobe University with a Bachelor of Faculty of Law in March 1985. He joined TOA Medical Electronics Co. Ltd. (presently Sysmex Corporation) in April 1985. His career progressed through various roles, including serving as President of Sysmex Europe GmbH (presently Sysmex Europe SE) from 2001 to 2005, and later as Executive Vice Chairman & CEO of Sysmex Europe GmbH from 2005 to 2007. He held the position of Executive Vice President of the Customer Support Division from 2007 to 2009, followed by Executive Vice President of the IVD Business Strategy Division from 2009 to 2011. From 2011 to 2013, he served as Executive Officer and Executive Vice President of Corporate Business Planning, and from 2013 to 2015, he was an Executive Officer and Executive Vice President of International Business Management. He then became a Senior Executive Officer from 2017 to 2019, and a Managing Director in 2019. He was appointed as a Member of the Managing Board and Senior Executive Officer in June 2019 and has held the same position since April 2023, also serving as a Senior Managing Director.공고 • Feb 09Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc.공고 • Dec 05Sysmex Corporation to Report Q3, 2026 Results on Feb 12, 2026Sysmex Corporation announced that they will report Q3, 2026 results on Feb 12, 2026공고 • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.공고 • Sep 04Sysmex Corporation to Report Q2, 2026 Results on Nov 05, 2025Sysmex Corporation announced that they will report Q2, 2026 results on Nov 05, 2025Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to Mex$246, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 16x in the Medical Equipment industry globally. Total loss to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$186 per share.공고 • Jun 25+ 1 more updateSysmex America, Inc. Receives FDA Clearance for Automated Blood Coagulation Analyzer CN-6000™?Sysmex America Inc. has received FDA clearance for the CN-6000 Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests: Prothrombin Time (PT) and PT INR with Dade®? Innovin®? Activated Partial Thromboplastin Time (APTT) with Dade®? Actin®? FSL; Fibrinogen (Fbg) with Dade®? Thrombin Reagent; Antithrombin (AT) with INNOVANCE®? Antithrombin; D-dimer with INNOVANCE D-Dimmer. Laboratories with high workloads may opt for the optional sampler that provides an expandable sample loading capacity. Sysmex will continue efforts to obtain market authorization for the Automated Blood Coagulation Analyzer CN-3000 and additional reagent applications.공고 • Jun 07Sysmex Corporation to Report Q1, 2026 Results on Aug 06, 2025Sysmex Corporation announced that they will report Q1, 2026 results on Aug 06, 2025공고 • May 15Sysmex Corporation, Annual General Meeting, Jun 27, 2025Sysmex Corporation, Annual General Meeting, Jun 27, 2025.공고 • Feb 28Sysmex Corporation to Report Fiscal Year 2025 Results on May 14, 2025Sysmex Corporation announced that they will report fiscal year 2025 results on May 14, 2025공고 • Oct 03D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869).D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024. Francesco Stella of Hogan Lovells acted as legal advisor for Sysmex Corporation. D-Group S.p.A. completed the acquisition of an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024.공고 • Jun 27+ 2 more updatesSysmex Corporation to Report Q3, 2025 Results on Feb 12, 2025Sysmex Corporation announced that they will report Q3, 2025 results on Feb 12, 2025공고 • May 12Sysmex Corporation, Annual General Meeting, Jun 21, 2024Sysmex Corporation, Annual General Meeting, Jun 21, 2024.공고 • Mar 08Sysmex Corporation to Report Fiscal Year 2024 Results on May 09, 2024Sysmex Corporation announced that they will report fiscal year 2024 results on May 09, 2024공고 • Feb 09Sysmex Corporation Reaffirm Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Sysmex Corporation announced year-end dividend for the fiscal year ending March 31, 2024, with a record date of March 31, 2024, will be paid on the shares before the stock split, because the effective date of the share split is April 1, 2024. The year-end dividend forecast for the fiscal year ending March 31, 2024 remains unchanged from that the announcement on May 11, 2023, which forecasts the year-end dividend of ¥42 per share.공고 • Nov 30Sysmex Corporation to Report Q3, 2024 Results on Feb 09, 2024Sysmex Corporation announced that they will report Q3, 2024 results on Feb 09, 2024공고 • Sep 08Sysmex Corporation to Report Q2, 2024 Results on Nov 08, 2023Sysmex Corporation announced that they will report Q2, 2024 results on Nov 08, 2023Valuation Update With 7 Day Price Move • Aug 15Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to Mex$922, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 23x in the Medical Equipment industry globally. Total loss to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at Mex$392 per share.Board Change • Aug 10Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.Board Change • Jul 12Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공고 • Jun 03Sysmex Corporation to Report Q1, 2024 Results on Aug 08, 2023Sysmex Corporation announced that they will report Q1, 2024 results at 3:00 PM, Tokyo Standard Time on Aug 08, 2023공고 • May 13Sysmex Corporation, Annual General Meeting, Jun 23, 2023Sysmex Corporation, Annual General Meeting, Jun 23, 2023.공고 • Feb 07Sysmex Corporation Announces Management ChangesSysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 7, 2023, to change the representative directors. Kaoru Asano appointed as President (Representative Director) from Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO. Appointment Date (Scheduled): April 1, 2023. Date of birth: October 19, 1958. Education: Graduate School of Engineering Osaka University, Division of Electronic Engineering. 2021- Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO; 2018-2021 Member of the Managing Board and Senior Executive Officer, Senior Managing Director, COO LS Business Unit and CTO; 2017-2018 Member of the Managing Board and Senior Executive Officer, Senior Managing Director; 2015-2017 Member of the Managing Board and Senior Executive Officer, Managing Director; 2014-2015 Appointed Member of the Managing Board and Senior Executive Officer. 2013-2014 -Appointed Senior Executive Officer, Executive Vice President of Central Research Laboratories; 2011-2013 Appointed Executive Officer, Executive Vice President of R&D Strategic Planning; 2009-2011 Appointed Executive Officer, Executive Vice President of Central Research Laboratories; Aug. 1987 Joined TOA Medical Electronics (presently Sysmex Corporation); Apr. 1983 Joined Kawasaki Heavy Industries Ltd.; March 1983 Graduated from Osaka University. Hisashi Ietsugu: Current: Chairman and CEO (Representative Director); New: Chairman and Group CEO, (Representative Director).Board Change • Jan 31Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.공고 • Jan 11Sysmex America, Inc. Appoints Chris Cappella as Chief Financial OfficerSysmex America Inc. announced that Chris Cappella has joined the Company as Chief Financial Officer. He will lead Sysmex America's regional finance organization and financial activities including accounting and controllership, financial planning and analysis, tax, internal audit and treasury. to joining Sysmex, Chris held a variety of finance leadership roles at Roche, most recently as the vice president of finance for Core Lab. At Roche, he was instrumental in driving growth through the cross-functional integration of agile strategies. Before his time at Roche, Chris was a finance manager at Brightpoint Inc. He started his career at Ernst & Young and is a Certified Public Accountant.공고 • Dec 01Sysmex Corporation to Report Q3, 2023 Results on Feb 09, 2023Sysmex Corporation announced that they will report Q3, 2023 results on Feb 09, 2023Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: JP¥38.38 (vs JP¥47.81 in 1Q 2022)First quarter 2023 results: EPS: JP¥38.38 (down from JP¥47.81 in 1Q 2022). Revenue: JP¥86.0b (up 8.4% from 1Q 2022). Net income: JP¥8.03b (down 20% from 1Q 2022). Profit margin: 9.3% (down from 13% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 14%, compared to a 19% growth forecast for the industry in Mexico.Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to Mex$1,421, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 23x in the Medical Equipment industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$988 per share.Board Change • Jul 18Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • May 30Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Upcoming Dividend • Mar 23Upcoming dividend of JP¥37.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Mexican dividend payers (5.4%). Lower than average of industry peers (1.4%).Board Change • Mar 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Feb 14Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Valuation Update With 7 Day Price Move • Jan 20Investor sentiment deteriorated over the past weekAfter last week's 28% share price decline to Mex$2,006, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 28x in the Medical Equipment industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$1,241 per share.Board Change • Jan 20Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Dec 17Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.Board Change • Sep 13Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.이익 및 매출 성장 예측BMV:6869 N - 애널리스트 향후 추정치 및 과거 재무 데이터 (JPY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수3/31/2028589,74066,10245,673102,196143/31/2027552,37760,08540,48795,884163/31/2026509,16850,95655,316111,093109/30/2025498,69146,68623,89776,177N/A6/30/2025502,42847,19127,92279,772N/A3/31/2025508,64353,66938,28788,246N/A12/31/2024501,85157,79036,79483,959N/A9/30/2024491,29153,45532,05083,365N/A6/30/2024478,10552,04920,18470,528N/A3/31/2024461,51049,63913,71463,905N/A12/31/2023438,28445,06317,88467,822N/A9/30/2023429,17843,98124,43571,237N/A6/30/2023419,82446,37532,65676,345N/A3/31/2023410,50245,78426,33068,835N/A12/31/2022403,62246,37710,93047,673N/A9/30/2022389,04945,83913,27149,778N/A6/30/2022370,44642,13014,59847,540N/A3/31/2022363,78044,09326,70558,739N/A12/31/2021352,12642,75538,11470,008N/A9/30/2021341,74442,73245,44172,223N/A6/30/2021323,92538,64836,70663,941N/A3/31/2021305,07333,14233,02058,813N/A12/31/2020295,66631,67532,52057,779N/A9/30/2020291,07229,94324,74150,094N/A6/30/2020293,95132,67327,96955,350N/A3/31/2020301,98034,88326,71053,182N/A12/31/2019303,29638,81321,01450,806N/A9/30/2019300,30239,34423,16352,225N/A6/30/2019296,08538,497N/A49,183N/A3/31/2019293,50641,224N/A44,743N/A12/31/2018287,75637,574N/A47,106N/A9/30/2018287,02239,502N/A48,028N/A6/30/2018286,17740,426N/A45,698N/A3/31/2018281,93539,222N/A52,240N/A12/31/2017271,65739,224N/A49,158N/A9/30/2017262,20736,345N/A41,613N/A6/30/2017252,45139,407N/A41,968N/A3/31/2017249,89940,636N/A32,832N/A12/31/2016248,26541,115N/A33,562N/A9/30/2016250,18442,910N/A37,052N/A6/30/2016254,68338,176N/A37,911N/A3/31/2016253,15736,233N/A39,567N/A12/31/2015251,20933,103N/A38,434N/A9/30/2015244,02830,712N/A38,559N/A6/30/2015232,28028,957N/A37,235N/A3/31/2015221,37626,638N/A38,640N/A12/31/2014210,54127,191N/A38,404N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: 6869 N 의 연간 예상 수익 증가율(12%)이 saving rate(8.7%)보다 높습니다.수익 vs 시장: 6869 N 의 연간 수익(12%)이 MX 시장(9.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 수익: 6869 N 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: 6869 N 의 수익(연간 6.6%)이 MX 시장(연간 6.2%)보다 빠르게 성장할 것으로 예상됩니다.고성장 매출: 6869 N 의 수익(연간 6.6%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: 6869 N의 자본 수익률은 3년 후 12.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YHealthcare 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2025/11/17 09:48종가2025/08/20 00:00수익2025/09/30연간 수익2025/03/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Sysmex Corporation는 27명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Masahiro NakanomyoBarclaysKei TakeuchiBofA Global ResearchHidemaru YamaguchiCitigroup Inc24명의 분석가 더 보기
공고 • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.
공고 • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.
공고 • Jun 06Sysmex Corporation to Report Q1, 2027 Results on Aug 07, 2026Sysmex Corporation announced that they will report Q1, 2027 results on Aug 07, 2026
공고 • May 15Sysmex Corporation, Annual General Meeting, Jun 26, 2026Sysmex Corporation, Annual General Meeting, Jun 26, 2026.
공고 • Apr 02Sysmex Corporation to Report Fiscal Year 2026 Results on May 14, 2026Sysmex Corporation announced that they will report fiscal year 2026 results at 3:30 PM, Tokyo Standard Time on May 14, 2026
공고 • Mar 26Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. Denka Company Limited intends to launch a Squeeze-Out Procedures, if it acquires the minimum tender shares (1,990,000 shares) and fails to acquire all of the KAINOS Laboratories, Inc's Shares (excluding the Shares Agreed Not to Be Tendered and treasury shares). The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Denka Company Limited (TSE:4061) completed the acquisition of 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders on March 25, 2026. Upon closing of the offer period, 3,223,919 shares were tendered. Since it is more than the minimum number of shares to be purchased (1,990,000 shares), Denka Company Limited will purchase all of the Tendered Share Certificates and intends to implement a series of procedures for the purpose of making the Tender Offeror the sole shareholder of KAINOS Laboratories, Inc. As of today, the KAINOS Laboratories, Inc's Shares are listed on the Standard Market of the Tokyo Stock Exchange. If the procedures are implemented, the KAINOS Laboratories, Inc's Shares will be delisted pursuant to the prescribed procedures, in accordance with the criteria for delisting of Tokyo Stock Exchange. KAINOS Laboratories, Inc's Shares, after being delisted, will no longer be traded on the Standard Market of the Tokyo Stock Exchange.
공고 • Mar 05Sysmex Corporation (TSE:6869) announces an Equity Buyback for 30,000,000 shares, representing 4.81% for ¥30,000 million.Sysmex Corporation (TSE:6869) announces a share repurchase program. Under the program, the company will repurchase up to 30,000,000 shares, representing 4.81% of its issued share capital, for ¥30,000 million. The program will be valid till September 18, 2026. The purpose of the program is to improve capital efficiency and enhance shareholder returns as well as active business investment for our future growth. The purchased shares will be cancelled. As of December 31, 2025, the company had 623,180,031 outstanding shares (excluding treasury stock) and 6,300,045 treasury shares.
공고 • Feb 13Sysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year period, the company expects net sales of JPY 500,000 million compared to previous guidance of JPY 510,000 million, operating profit of JPY 62,000 million compared to previous guidance of JPY 76,000 million and profit attributable to owners of the parent of JPY 41,000 million or JPY 65.77 per basic share compared to previous guidance of JPY 45,000 million or JPY 72.19 per basic share.
공고 • Feb 12Sysmex Corporation Announces Executive and Board Changes, Effective April 1, 2026Sysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 12, 2026, to change the representative directors as stated below. Reasons for Change. To further strengthen management structure in order to enhance corporate value. Iwane Matsui has been newly appointed as the President (Representative Director), while previously serving as Member of the Managing Board and Senior Executive Officer, Senior Managing Director. Kaoru Asano appointed as the Member of the Managing Board, from currently holding the title of President (Representative Director). Effective Date of Transfer: April 1, 2026. Kaoru Asano is scheduled to resign from the Member of the Managing Board at the Ordinary General Meeting of Shareholders to be held in June 2026 and subsequently serve as Senior Executive Advisor. There are no changes to Hisashi Ietsugu's current position as Chairperson and Group CEO. Iwane Matsui was born on January 1, 1961, and graduated from Kobe University with a Bachelor of Faculty of Law in March 1985. He joined TOA Medical Electronics Co. Ltd. (presently Sysmex Corporation) in April 1985. His career progressed through various roles, including serving as President of Sysmex Europe GmbH (presently Sysmex Europe SE) from 2001 to 2005, and later as Executive Vice Chairman & CEO of Sysmex Europe GmbH from 2005 to 2007. He held the position of Executive Vice President of the Customer Support Division from 2007 to 2009, followed by Executive Vice President of the IVD Business Strategy Division from 2009 to 2011. From 2011 to 2013, he served as Executive Officer and Executive Vice President of Corporate Business Planning, and from 2013 to 2015, he was an Executive Officer and Executive Vice President of International Business Management. He then became a Senior Executive Officer from 2017 to 2019, and a Managing Director in 2019. He was appointed as a Member of the Managing Board and Senior Executive Officer in June 2019 and has held the same position since April 2023, also serving as a Senior Managing Director.
공고 • Feb 09Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion.Denka Company Limited (TSE:4061) proposed to acquire 77.65% stake in KAINOS Laboratories, Inc. (TSE:4556) from a group of shareholders for ¥7.9 billion on February 6, 2026. A cash consideration of ¥7.89 billion valued at ¥2285 per share will be paid by Denka Company Limited. As part of consideration, ¥7.89 billion is paid towards common equity of KAINOS Laboratories, Inc. The transaction is subject to minimum tender. The expected completion of the transaction is March 25, 2026. Sumitomo Mitsui Banking Corporation acted as financial advisor for Denka Company Limited. AGS Consulting Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc. Nagashima Ohno & Tsunematsu acted as legal advisor for KAINOS Laboratories, Inc. TMI Associates acted as legal advisor for KAINOS Laboratories, Inc. Mizuho Securities Co., Ltd. acted as financial advisor for KAINOS Laboratories, Inc.
공고 • Dec 05Sysmex Corporation to Report Q3, 2026 Results on Feb 12, 2026Sysmex Corporation announced that they will report Q3, 2026 results on Feb 12, 2026
공고 • Nov 06+ 2 more updatesSysmex Corporation Revises Consolidated Earnings Guidance for the Year Ending March 31, 2026Sysmex Corporation revised consolidated earnings guidance for the year ending March 31, 2026. For the year ending March 31, 2026, the company expects net sales of JPY 510,000 million compared to previous guidance of JPY 535,000 million, operating profit of JPY 76,000 million compared to previous guidance of JPY 91,500 million and profit attributable to owners of the parent of JPY 45,000 million or JPY 72.19 per basic share compared to previous guidance of JPY 57,000 million or JPY 91.40 per basic share. Reasons for Forecast Revision: Although the company worked to control selling, general and administrative (SG&A) expenses, the company was unable to offset the decline in profit resulting from lower-than-expected net sales. As a result, operating profit, profit before tax, and profit attributable to owners of the parent all fell below the previous forecast. As for its forecast for the full fiscal year ending March 31, 2026, it will continue working to improve profitability and control SG&A expenses. However, given the expectation that sales in the China and Japan regions will remain below initial projections, the company is revising its forecast to reflect anticipated declines in net sales, operating profit, profit before tax, and profit attributable to owners of the parent.
공고 • Sep 04Sysmex Corporation to Report Q2, 2026 Results on Nov 05, 2025Sysmex Corporation announced that they will report Q2, 2026 results on Nov 05, 2025
Valuation Update With 7 Day Price Move • Aug 20Investor sentiment deteriorates as stock falls 23%After last week's 23% share price decline to Mex$246, the stock trades at a forward P/E ratio of 21x. Average forward P/E is 16x in the Medical Equipment industry globally. Total loss to shareholders of 43% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at Mex$186 per share.
공고 • Jun 25+ 1 more updateSysmex America, Inc. Receives FDA Clearance for Automated Blood Coagulation Analyzer CN-6000™?Sysmex America Inc. has received FDA clearance for the CN-6000 Automated Blood Coagulation Analyzer. This clearance includes the reagent products used in five commonly performed hemostasis tests: Prothrombin Time (PT) and PT INR with Dade®? Innovin®? Activated Partial Thromboplastin Time (APTT) with Dade®? Actin®? FSL; Fibrinogen (Fbg) with Dade®? Thrombin Reagent; Antithrombin (AT) with INNOVANCE®? Antithrombin; D-dimer with INNOVANCE D-Dimmer. Laboratories with high workloads may opt for the optional sampler that provides an expandable sample loading capacity. Sysmex will continue efforts to obtain market authorization for the Automated Blood Coagulation Analyzer CN-3000 and additional reagent applications.
공고 • Jun 07Sysmex Corporation to Report Q1, 2026 Results on Aug 06, 2025Sysmex Corporation announced that they will report Q1, 2026 results on Aug 06, 2025
공고 • May 15Sysmex Corporation, Annual General Meeting, Jun 27, 2025Sysmex Corporation, Annual General Meeting, Jun 27, 2025.
공고 • Feb 28Sysmex Corporation to Report Fiscal Year 2025 Results on May 14, 2025Sysmex Corporation announced that they will report fiscal year 2025 results on May 14, 2025
공고 • Oct 03D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869).D-Group S.p.A. acquired an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024. Francesco Stella of Hogan Lovells acted as legal advisor for Sysmex Corporation. D-Group S.p.A. completed the acquisition of an unknown minority stake in Dasit S.p.A. from Sysmex Corporation (TSE:6869) on October 2, 2024.
공고 • Jun 27+ 2 more updatesSysmex Corporation to Report Q3, 2025 Results on Feb 12, 2025Sysmex Corporation announced that they will report Q3, 2025 results on Feb 12, 2025
공고 • May 12Sysmex Corporation, Annual General Meeting, Jun 21, 2024Sysmex Corporation, Annual General Meeting, Jun 21, 2024.
공고 • Mar 08Sysmex Corporation to Report Fiscal Year 2024 Results on May 09, 2024Sysmex Corporation announced that they will report fiscal year 2024 results on May 09, 2024
공고 • Feb 09Sysmex Corporation Reaffirm Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024Sysmex Corporation announced year-end dividend for the fiscal year ending March 31, 2024, with a record date of March 31, 2024, will be paid on the shares before the stock split, because the effective date of the share split is April 1, 2024. The year-end dividend forecast for the fiscal year ending March 31, 2024 remains unchanged from that the announcement on May 11, 2023, which forecasts the year-end dividend of ¥42 per share.
공고 • Nov 30Sysmex Corporation to Report Q3, 2024 Results on Feb 09, 2024Sysmex Corporation announced that they will report Q3, 2024 results on Feb 09, 2024
공고 • Sep 08Sysmex Corporation to Report Q2, 2024 Results on Nov 08, 2023Sysmex Corporation announced that they will report Q2, 2024 results on Nov 08, 2023
Valuation Update With 7 Day Price Move • Aug 15Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to Mex$922, the stock trades at a forward P/E ratio of 30x. Average forward P/E is 23x in the Medical Equipment industry globally. Total loss to shareholders of 29% over the past year. Simply Wall St's valuation model estimates the intrinsic value at Mex$392 per share.
Board Change • Aug 10Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
Board Change • Jul 12Less than half of directors are independentFollowing the recent departure of a director, there are only 5 independent directors on the board. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공고 • Jun 03Sysmex Corporation to Report Q1, 2024 Results on Aug 08, 2023Sysmex Corporation announced that they will report Q1, 2024 results at 3:00 PM, Tokyo Standard Time on Aug 08, 2023
공고 • May 13Sysmex Corporation, Annual General Meeting, Jun 23, 2023Sysmex Corporation, Annual General Meeting, Jun 23, 2023.
공고 • Feb 07Sysmex Corporation Announces Management ChangesSysmex Corporation announced that it has resolved, at a meeting of the Board of Directors held on February 7, 2023, to change the representative directors. Kaoru Asano appointed as President (Representative Director) from Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO. Appointment Date (Scheduled): April 1, 2023. Date of birth: October 19, 1958. Education: Graduate School of Engineering Osaka University, Division of Electronic Engineering. 2021- Member of the Managing Board and Senior Executive Officer, Senior Managing Director, CTO; 2018-2021 Member of the Managing Board and Senior Executive Officer, Senior Managing Director, COO LS Business Unit and CTO; 2017-2018 Member of the Managing Board and Senior Executive Officer, Senior Managing Director; 2015-2017 Member of the Managing Board and Senior Executive Officer, Managing Director; 2014-2015 Appointed Member of the Managing Board and Senior Executive Officer. 2013-2014 -Appointed Senior Executive Officer, Executive Vice President of Central Research Laboratories; 2011-2013 Appointed Executive Officer, Executive Vice President of R&D Strategic Planning; 2009-2011 Appointed Executive Officer, Executive Vice President of Central Research Laboratories; Aug. 1987 Joined TOA Medical Electronics (presently Sysmex Corporation); Apr. 1983 Joined Kawasaki Heavy Industries Ltd.; March 1983 Graduated from Osaka University. Hisashi Ietsugu: Current: Chairman and CEO (Representative Director); New: Chairman and Group CEO, (Representative Director).
Board Change • Jan 31Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
공고 • Jan 11Sysmex America, Inc. Appoints Chris Cappella as Chief Financial OfficerSysmex America Inc. announced that Chris Cappella has joined the Company as Chief Financial Officer. He will lead Sysmex America's regional finance organization and financial activities including accounting and controllership, financial planning and analysis, tax, internal audit and treasury. to joining Sysmex, Chris held a variety of finance leadership roles at Roche, most recently as the vice president of finance for Core Lab. At Roche, he was instrumental in driving growth through the cross-functional integration of agile strategies. Before his time at Roche, Chris was a finance manager at Brightpoint Inc. He started his career at Ernst & Young and is a Certified Public Accountant.
공고 • Dec 01Sysmex Corporation to Report Q3, 2023 Results on Feb 09, 2023Sysmex Corporation announced that they will report Q3, 2023 results on Feb 09, 2023
Board Change • Nov 16Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Reported Earnings • Aug 05First quarter 2023 earnings released: EPS: JP¥38.38 (vs JP¥47.81 in 1Q 2022)First quarter 2023 results: EPS: JP¥38.38 (down from JP¥47.81 in 1Q 2022). Revenue: JP¥86.0b (up 8.4% from 1Q 2022). Net income: JP¥8.03b (down 20% from 1Q 2022). Profit margin: 9.3% (down from 13% in 1Q 2022). The decrease in margin was driven by higher expenses. Over the next year, revenue is forecast to grow 14%, compared to a 19% growth forecast for the industry in Mexico.
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment improved over the past weekAfter last week's 17% share price gain to Mex$1,421, the stock trades at a forward P/E ratio of 38x. Average forward P/E is 23x in the Medical Equipment industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$988 per share.
Board Change • Jul 18Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 3 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • May 30Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Upcoming Dividend • Mar 23Upcoming dividend of JP¥37.00 per shareEligible shareholders must have bought the stock before 30 March 2022. Payment date: 28 June 2022. Payout ratio is a comfortable 36% and this is well supported by cash flows. Trailing yield: 0.9%. Lower than top quartile of Mexican dividend payers (5.4%). Lower than average of industry peers (1.4%).
Board Change • Mar 16Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Feb 14Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Valuation Update With 7 Day Price Move • Jan 20Investor sentiment deteriorated over the past weekAfter last week's 28% share price decline to Mex$2,006, the stock trades at a forward P/E ratio of 49x. Average forward P/E is 28x in the Medical Equipment industry globally. Simply Wall St's valuation model estimates the intrinsic value at Mex$1,241 per share.
Board Change • Jan 20Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Dec 17Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.
Board Change • Sep 13Less than half of directors are independentThere are 7 new directors who have joined the board in the last 3 years. Of these new board members, 4 were independent directors. The company's board is composed of: 5 independent directors. 7 non-independent directors. Independent Outside Member of the Managing Board Hidekazu Fukumoto was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity.